David Grinblatt to Treatment Outcome
This is a "connection" page, showing publications David Grinblatt has written about Treatment Outcome.
Connection Strength
0.142
-
The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research. Oncologist. 2023 08 03; 28(8):657-663.
Score: 0.095
-
Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec; 175(5):892-903.
Score: 0.015
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.010
-
Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transplant. 2006 Jul; 38(2):95-100.
Score: 0.007
-
Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 Mar; 37(6):553-7.
Score: 0.007
-
Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. J Clin Apher. 1999; 14(1):31-4.
Score: 0.004
-
Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant. 1995 Jun; 15(6):935-42.
Score: 0.003